Fionnuala received her PhD (Microbiology) from Trinity College Dublin in 2002. Her post-doctoral studies were carried out at Wyeth Pharmaceuticals (NY) where she worked on S. aureus antibiotic resistance mechanisms. She then transferred to the Global Biologics organization at Wyeth (Cambridge, MA; acquired by Pfizer in 2009) as a Senior Scientist working primarily with phage display in the antibody lead discovery department with a focus on cancer, inflammatory and infectious diseases. In 2010, she moved to Heidelberg Germany in a role as Head of Antibody Lead Discovery for Affimed, generating bispecific NK and T-cell engagers for the treatment of cancer. Since 2013, Fionnuala has been a Group Leader in the Antibody Lead Discovery department within Biologics Research at Bayer with a primary focus on biotherapeutic discovery for cardiovascular indications (Cologne, Germany).